← Back to Clinical Trials
Recruiting NCT07637383

NCT07637383 IMPACT OF A MULTICOMPONENT PHYSICAL EXERCISE PROGRAM ON THE FUNCTIONAL CAPACITY OF PATIENTS ADMITTED TO AN INTERMEDIATE CARE HOSPITAL. VIVIFRAIL FOR A BETTER VIG-FRAIL.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07637383
Status Recruiting
Phase
Sponsor Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Condition Functionality
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2026-02-18
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
vivifrail

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2026-02-18 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

INTRODUCTION Physical exercise in frail individuals has demonstrated benefits in variables such as reduced mortality risk and improved frailty and quality of life. Specifically, the most beneficial type appears to be multicomponent exercise, which includes strength, endurance, balance, and gait training. Within this field, the VIVIFRAIL project is an internationally recognized physical exercise promotion program. OBJECTIVES To analyze the effects of an individualized multicomponent physical exercise program as an effective method for preventing/improving functional status and frailty in individuals admitted to an intermediate care hospital (ICH). To assess whether improvements in functionality/frailty are maintained 3-4 months after discharge and to evaluate the impact of the program on quality of life variables and health indicators at 6 months. METHODOLOGY Design: randomized clinical trial with two groups (control and intervention) and 6 months of follow-up. Study population: adults older than 65 years admitted to an intermediate care hospital (ICH). Inclusion criteria: baseline Barthel Index ≥60, ability to communicate, ambulate, and complete the exercise program. Primary variables: functionality (Short Physical Performance Battery - SPPB) and frailty (Frail-VIG Index). Secondary variables: grip strength, depressive symptoms, fear of falling, mortality, institutionalization, hospital admissions/emergency room and primary care visits, level of physical activity, medications (number, analgesics, opioid use, antidepressants, anxiolytics), and quality of life. Sample size: assuming a 15% loss to follow-up, the final required sample size is 120 patients. Linear mixed-effects models will be used with a significance level of 0.05.

Eligibility Criteria

* baseline Barthel Index ≥60 * ability to communicate, ambulate, and complete the exercise program

Contact & Investigator

Central Contact

Raquel Gómez Cortijo

✉ rgomezcortijo@gmail.com

📞 938743312

Frequently Asked Questions

Who can join the NCT07637383 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Functionality. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07637383 currently recruiting?

Yes, NCT07637383 is actively recruiting participants. Contact the research team at rgomezcortijo@gmail.com for enrollment information.

Where is the NCT07637383 trial being conducted?

This trial is being conducted at Manresa, Spain.

Who is sponsoring the NCT07637383 clinical trial?

NCT07637383 is sponsored by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology